Allogeneic hematopoietic stem cell transplant (AHSCT) outcomes data of older AML/myelodysplastic syndrome (MDS) patients are limited. We retrospectively evaluated consecutive patients ⩾ 60 years old with AML/MDS who underwent AHSCT between January 2005 and December 2014. The primary objectives were to determine nonrelapse mortality (NRM), relapse, relapse-free survival (RFS) and overall survival (OS) at 1 year post AHSCT. A total of 159 patients underwent AHSCT with a median age of 64 (range, 60-75) years. Of these, 103 patients (65%) had AML and 56 patients (35%) had MDS. At 1 year post AHSCT, grade III-IV acute GvHD and chronic GvHD occurred in 20.8% (95% confidence interval (CI), 14.9-27.5%) and 54.1% (95% CI, 46.0-61.5%) of patients, respectively. NRM, RFS, relapse rate and OS at 1 year post AHSCT were 25.3% (95% CI, 18.8-32.3%), 53.3% (95% CI, 46.1-61.7%), 21.4% (95% CI, 15.4-28.1%) and 56.4% (95% CI, 49.2-54.7%), respectively. High disease risk index was associated with poor RFS, OS and higher relapse rate (P o 0.03), whereas non-thymoglobulin-based GvHD prophylaxis, higher comorbidity index (⩾3) and MDS were associated with higher NRM (P o 0.03). Importantly, age did not have an adverse effect on NRM, relapse, RFS and OS. AHSCT was well tolerated. Hence, older age alone should not be considered a contraindication to AHSCT. 1 Older patients with AML and MDS represent a discrete group of patients with a different disease biology.
INTRODUCTION
AML and myelodysplastic syndrome (MDS) are clonal diseases involving hematopoietic stem cells with a median age of onset of 67 years and 70 years, respectively. 1 Older patients with AML and MDS represent a discrete group of patients with a different disease biology. 2 Various disease-and patient-related factors account for poor outcomes. These include higher frequency of unfavorable cytogenetics, lower incidence of favorable cytogenetics, increased anthracyclines resistance secondary to multidrug resistance phenotype (MDR1) and P-glycoprotein (gp170) chemotherapy efflux pump, increased proportion of secondary AML arising from MDS, multiple comorbid conditions, poor performance status and limited availability of related donors because of advanced age. 2, 3 Moreover, age-related pharmacokinetic and pharmacodynamic changes and weakened immunity result in poor tolerability to chemotherapy, and predispose them to increased morbidity and mortality. 4 Therefore, odds of achieving CR1 and long-term leukemia-free survival with conventional chemotherapy among these patients are 55-80% and 10-15%, respectively. 5, 6 Allogeneic hematopoietic stem cell transplantation (AHSCT) remains a successful treatment modality for both diseases, especially with intermediate-and high-risk category. 7 However, toxicities associated with myeloablative conditioning regimen often preclude older patients the opportunity to use potentially lifesaving modality. [8] [9] [10] A phase III study demonstrated lower relapse rate and superior relapse-free survival (RFS) with myeloablative conditioning regimen but it was offset by higher transplant-related mortality. 11 Reduced-intensity conditioning (RIC) regimen is another alternative that is well tolerated and offers comparable disease-free survival and nonrelapse mortality (NRM). [12] [13] [14] [15] It is well recognized that patient selection may be partially responsible for success of RIC. Despite favorable outcomes of RIC transplant in older patients, a common misperception of higher NRM among older patients still prevails among physicians. Thus, the number of older patients referred for AHSCT evaluation remains small. Essentially all older patients are excluded from prospective trials because of arbitrary age cutoff of 50-55 years, and thus data on AHSCT in older patients are limited. Moreover, the available trials have showed inconclusive associations between age and transplant outcomes. [16] [17] [18] [19] [20] To better define this, we conducted a retrospective review of patients ⩾ 60 years of age who received AHSCT for AML and MDS at our institution.
MATERIALS AND METHODS
We conducted a retrospective study of patients ⩾ 60 years old who underwent AHSCT for AML and MDS between January 2005 and December 2014 at Karmanos Cancer Institute. Patients with cord blood or haploidentical transplantation were excluded to avoid heterogeneity. This study was approved by Wayne State University institutional review board.
The Karmanos Cancer Institute Blood and Marrow Transplant Program database was used. Demographic and transplant details for all patients were collected. Disease status at transplant was grouped into 'complete remission' (CR), 'not complete remission' (non-CR) and 'untreated' (URx) groups. Non-CR group included progressive disease, primary induction failure, relapse and stable disease. Patients with AML were further classified into low, intermediate, high and very high disease risk index (DRI) based on cytogenetics at diagnosis (NCCN (National Comprehensive Cancer Network) categories) and disease status at transplant. 21 MDS patients were grouped into 4 groups (low, intermediate-1, intermediate-2 and high) based on IPSS (International Prognostic Scoring System) criteria. 22 Comorbidity index (CI) was calculated using HSCT-CI formula. 23 Patients' records were reviewed to determine acute and chronic GvHD and followed till the last follow-up or death.
Outcome measures
The primary end points were to determine NRM, relapse rate, RFS and overall survival (OS) at 1 year post AHSCT. The secondary objectives were to estimate cumulative incidence and severity of acute GvHD (aGvHD) and chronic GvHD (cGvHD) at 1 year, GvHD-free relapse-free survival (GRFS), length of stay and readmission rate in the first 100 days following transplant.
Preparative regimen
The choice of preparative regimen was determined by the treating physician. Full-intensity regimen included: IV busulfan 130 mg/m 2 daily for 4 days (days − 6 to − 3) and IV fludarabine 30 mg/m 2 daily for 5 days (days − 6 to − 2). RIC regimen included IV busulfan 130 mg/m 2 daily for 2 days (days − 6 and − 5), IV fludarabine 30 mg/m 2 daily for 5 days (days − 6 to − 2) and TBI 200 cGy (day 0). The actual dose of busulfan delivered was adjusted to target the daily area under the curve for busulfan of 5000 μMol × min.
GvHD prophylaxis
The GvHD prophylaxis was selected by the treating physician. Rabbit antithymocyte globulin (ATG) at a total dose of 4.5 mg/kg was given in divided doses (day − 3: 0.5 mg/kg; day − 2: 1.5 mg/kg; and day − 1: 2.5 mg/kg). Tacrolimus was IV administered (0.03 mg/kg/day) starting on day − 3 and tapered starting around day +100 in the absence of active GvHD with a goal of tapering off completely by day +180. Sirolimus was given on day − 3 with a 12 mg loading oral dose, followed by 4 mg daily beginning on day − 2 onwards. Mycophenolate was initiated at 15 mg/kg twice daily from day − 3 and stopped at day +30.
Supportive care
All patients received standard antimicrobial prophylaxis consisting of fluoroquinolone, fluconazole and acyclovir. G-CSF (5 μg/kg) was started at day +6 until engraftment. CMV was monitored weekly by blood PCR. Patients with PCR titers 41000 copies/ml were treated with ganciclovir. Patients received Pneumocystis prophylaxis with double strength trimethoprim/sulfamethoxazole twice weekly started on day +30 post transplant. Weekly EBV PCR surveillance was started on day +20 and continued until day +120 post transplant. Patients with EBV PCR41000 genome copies/ml were treated with one dose of rituximab. Additional doses were used if no decline in viral load was seen following the first dose.
Statistical analysis
Baseline patient characteristics were summarized using count and percentage for categorical variables and median and range for continuous variables. Patient characteristics were compared between two diagnosis groups (AML and MDS) and two age groups (age ⩽ 65 and 465 years), respectively. Kruskal-Wallis tests were used to compare age groups for continuous variables. Fisher's exact tests were used to compare age groups for categorical variables. The length of hospital stay was calculated as the time from the date of admission before transplant to the date of discharge post transplant. OS was calculated as the time from the date of transplant to death from any cause. Patients who were alive were censored at the date of last observation. RFS was calculated as the time from the date of transplant to the date of relapse or death from any cause. Patients who were alive without relapse were considered censored at the date of last observation. Composite end point of GRFS was calculated as the time from the date of transplantation to the date of grade III-IV aGvHD, cGvHD requiring treatment, relapse or death from any cause. 24 Patients who were alive without grade III-IV aGvHD, grade E1-E3 cGvHD, relapse and death were censored at the date of last observation. Kaplan-Meier estimates were used to summarize the distribution of OS, RFS and GRFS. The cumulative incidences of acute and chronic GvHD were calculated with relapse or death without GvHD as competing risks. When calculating the cumulative incidence of grade III-IV aGvHD, the events of grade I-II aGvHD were ignored. The cumulative incidences of relapse and NRM were calculated with death without relapse for relapse and disease relapse for NRM, respectively, as competing risks. Univariable and multivariable Cox proportional hazards regression models were fit to assess associations between seven prior chosen predictors (age at transplant, diagnosis, transplant type, DRI, comorbidity, conditioning regimen, GvHD prophylaxis and CMV match) and survival benefit (GRFS, RFS and OS). For relapse and NRM, the proportional subdistribution hazards regression model in competing risks was used for univariable and multivariable analyses with the seven predetermined covariates. The proportional hazards assumption was assessed and no violation was found. In addition, the covariate age was further separated into two groups (age ⩾ 60 and ⩽ 65, 465 and ⩽ 75) and used for the univariable and multivariable Cox and subdistribution proportional hazards regression models. Note that because of the retrospective nature of this study, observed power is determined completely by the P-value of each analysis. 25 
RESULTS

Baseline characteristics
A total of 159 patients underwent AHSCT. Of these, 103 (65%) patients had AML and 56 (35%) had MDS (Table 1) . Of the AML patients, 67 (42%) had de novo and 36 (23%) had secondary AML. The patients with secondary AML had previous MDS, 16 myeloproliferative disorders, 13 and therapy-related AML. 7 The patients were divided into 2 groups: ⩽ 65 years and 465 years old. More patients in ⩽ 65 years of age were untreated (19% vs 4%) and underwent 7/8 transplant (17% vs 4%), whereas patients with 465 years of age had increased use of RIC regimen (87% vs 60%) and non-thymoglobulin-based GvHD prophylaxis (62% vs 42%) (Supplementary Table S1 ).
The median time from diagnosis to AHSCT was 154 (range, 16-3716) days. The median length of hospitalization following transplant was 26 (range, 19-112) days and half of patients (52%) were readmitted within the first 100 days.
Engraftment and GvHD
The median times to neutrophil and platelet engraftment were 11 (range, 7-22) days and 16 (range, 0-675) days post AHSCT, respectively. Primary graft failure was observed in 2 patients and both required second transplantations, whereas secondary graft failure was seen in one patient at day +233 post AHSCT.
In all, 65 patients (41%) developed grade II-IV aGvHD, with a cumulative incidence of 39.7% (95% confidence interval (CI), 32-47.2) at 1 year. The median time to development of grade II-IV aGvHD was 32 (95% CI, 28-37) days. Of these patients, 51 (78%) were 8/8 HLA matched, and 13 patients (20%) were 7/8 matched. Thirty-five patients (22%) developed grade III-IV aGvHD, with a cumulative incidence of 20.8% (95% CI, 14.9-27.5) at 1 year (Figure 1a ). Of these patients, 26 (74%) were 8/8 matched and 9 patients (26%) were 7/8 matched. Two patients developed aGvHD beyond day +100 (Supplementary Table S2 ). Seventy-six patients developed cGvHD, with a cumulative incidence of 54.1% (95% CI, 46-61.5) at 1 year (Figure 1b) . The cumulative incidence of extensive cGvHD was 39.8% (95% CI, 32.1-47.4). The median time to development of both limited and extensive cGvHD was 165 (95% CI, 145-194) days. Mild, moderate and severe extensive cGvHD were noted in 26 (16%), 25 (16%) and 17 (11%) patients, respectively, and bronchiolitis obliterans was developed in 19 patients. Transplant Abbreviations: BMT = bone marrow transplant; IPSS = International Prognostic Scoring System; MDS = myelodysplastic syndrome; RAEB-1 = refractory anemia with excess blasts-1; RAEB-2 = refractory anemia with excess blasts-2; RARS = refractory anemia with ringed sideroblasts; RCMD = refractory cytopenia with multilineage dysplasia; RCUD = refractory cytopenia with unilineage dysplasia; Signif = significance. (Figure 2a ). Of these patients, 10 (76%) received full-intensity conditioning regimen and 32 patients (24%) had RIC regimen. The median time to progression was 101 days (range, 12-1120). Twenty-one patients had disease progression within +100 days, 13 patients progressed between +100 days and 1 year and 8 patients progressed beyond 1 year. The relapses differed significantly by donor type that is, 67% had an unrelated donor compared with 33% with a related donor. Four patients received donor lymphocytes infusions and three underwent second transplantation. Twenty patients developed post-transplant large granular lymphocytosis. The multivariate analysis demonstrated AML, high and very high DRI and higher CI (⩾3) (P o0.004) to be associated with higher relapse rate. There was no difference in relapse in patients ⩽ 65 and 465 years of age (Supplementary Table S3 ).
Non-relapse mortality The cumulative incidence of NRM at 1 year post AHSCT was 25.3% (95% CI, 18.8-32.3) (Figure 2b ). The factors associated with higher NRM in multivariate analysis were MDS, higher CI (⩾3) and nonthymoglobulin-based GVHD prophylaxis (P o0.03); however, age, Table S3 ).
RFS, GRFS and OS
The median follow-up of living patients was 3.3 (95% CI, 2.51-3.87) years. At 1 year, the cumulative incidence of RFS was 53.3% (95% CI, 46.1-61.7) and GRFS was 35%. OS probability at 1 year was 56.4% (95% CI, 49.2-54.7) (Figure 3) . The median OS was 1.6 (95% CI, 0.936-4.997) years. On multivariate analysis, patients with high and very high DRI had worse RFS (P = 0.017), GRFS (P = 0.021) and poor OS (P = 0.032) compared with patients with low or intermediate DRI, whereas a favorable trend was noticed with thymoglobulin-based GvHD prophylaxis. No difference in RFS, GRFS and OS was observed between patients ⩽ 65 and465 years of age (Supplementary Table S4) .
Eighty-nine patients died at a median of 135 (range, 15-2118) days post AHSCT. The causes of death were recurrence of leukemia (45%), multiorgan failure (24%), aGvHD (18%), cGvHD (12%), graft rejection (2%) and new malignancy (1%).
DISCUSSION
Management of older AML and MDS patients is challenging and there is no consensus regarding optimal induction chemotherapy and consolidation AHSCT. This is a critical issue as the number of older AML and MDS patients is expected to increase with an aging population. Our study demonstrated that AHSCT was well tolerated in older patients and older age had no impact on NRM, relapse rate, RFS, GFRS and OS. Compared with expected outcomes without AHSCT in this age group, this group of selected patients did much better. 5, 6 Like previous studies, an increased number of older patients underwent AHSCT in recent years. 26, 27 However, the proportion of older patients referred for AHSCT remains limited, often because of unfounded bias regarding appropriate age for transplant.
Our study revealed an acceptable rate of grade III-IV aGvHD. 28, 29 However, a higher rate of cGvHD was noticed that was consistent with previous studies. 16, 30 The higher cGvHD could possibly be attributed to more patients who underwent peripheral stem cells and more use of unrelated donors because of unavailability of sibling donors. 16, 31, 32 Devine et al. 33 reported relatively lower rates of acute and chronic GvHD with the incorporation of higher dose of rabbit thymoglobulin (7.5 vs 4.5 mg/kg). We observed a favorable effect of thymoglobulinbased GvHD prophylaxis on NRM, whereas positive trend on RFS and OS was noted. These results could most likely be attributed to a reduction of incidence and/or severity of GVHD as noticed in prior studies. [34] [35] [36] Despite higher use of RIC and T cell-depleting agents, relatively lower relapse rate was noticed in our study. We predominantly used busulfan/fludarabine/TBI as RIC regimen compared with fludarabine/busulfan or fludarabine/melphalan used in the BMT CTN (Blood and Marrow Transplant Clinical Trials Network) study by Scott et al. 37 We recently presented our experience with AML/ MDS patients and found no difference in RFS and OS between myeloablative regimen and TBI containing RIC regimen. 38 In our opinion, addition of TBI might have further increased effectiveness of busulfan/fludarabine and lowered relapse rate. The relapse rate was lower compared with the study of Devine et al. 33 Probably, the relatively lower dose of thymoglobulin in our study might have impacted relapse rate. Soiffer et al. 39 observed higher relapse rate (51% vs 38%), poor RFS (25% vs 39%) and OS (38% vs 46%) with ATG in RIC regimen AHSCT. However, in this study, rabbit ATG was given at a dose of 7 mg/kg, whereas we utilized rabbit ATG at a dose of 4.5 mg/kg. We think that higher dose of ATG could be responsible for higher relapse rate, posttransplant lymphoproliferative disease (PTLD) and poor RFS. Similar associations between ATG dose and relapse were noted in previous studies. In a study by Deeg et al., 40 optimal GvHD benefit was noticed with thymoglobulin 4.5 to 6 mg/kg with no increased risk of relapse or EBV reactivation. Furthermore, improved NRM and infection rates were observed with reduced dose of thymoglobulin. 41 Our study demonstrated higher CI as one of the adverse factors for relapse and NRM. The higher CI is associated with increased risk of GvHD and eventually higher NRM as seen in previous studies. 29, 42, 43 High and very high DRI have emerged as important factors predicting higher relapse rate and poor RFS, GRFS and OS in our study. Our study showed significant survival benefit in patients with intermediate/low DRI, consistent with studies by Koreth et al. 7 and Fukuda and colleagues. 44 One of the impediments in determining AHSCT eligibility of older patients is donor availability. Often, finding a related donor becomes difficult as potential donors are old and comorbidities exclude them from stem cell donation. Fukuda and colleagues 44 and Lim et al. 45 noticed lower incidence of NRM among related donor transplants; however, we observed no effect of donor type on transplant outcomes including NRM. These results imply that limited availability of matched related donor should not be a barrier to AHSCT. Previous studies have revealed better NRM and OS in older AML patients undergoing AHSCT with CR1. 44, 46 In contrast, our study included patients who were not in complete remission. Despite this, no negative impact on NRM, relapse rate or RFS was observed.
Our observed GRFS rate is comparable to the study of Holtan et al. 24 They noted donor type, age, DRI and year of transplant to be independent predictors for GRFS. Our study supported the effect of DRI on GRFS, whereas age and donor type had no impact on GRFS.
Our study is retrospective and limited to a single center. However, presence of higher median CI (⩾3) and high to very high DRI in more than half of the patients speak against any selection bias in our study.
In conclusion, our results indicate that biologic age alone should not be the only criterion in determining transplant eligibility. Instead, a careful consideration should be given to patient characteristics including comorbid conditions, and disease characteristics including cytogenetic abnormalities, and disease status at transplant. Moreover, the beneficial effect of thymoglobulinbased GvHD regimen on NRM stipulates its potential role in this patient population. Because of the nature of disease, prompt decision should be made to refer these patients for AHSCT consideration to achieve better outcomes. Figure 3 . OS, RFS and GRFS estimates.
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